ARCHIVES

In Brief: Hammond Resigned As ACS Officer; Wykoff Slated To Direct FDA Special Populations Office

This article is from The Cancer Letter archive.

Vol. 18 No. 45 | November 20, 1992

Download PDF Visit The Full Archive

Related Articles

Banned Investigator Plans To Resume Clinical Trials Role

August 10, 1990

Phase III Trial Retrospective Analysis Finds Talimogene Laherparepvec Reduced Tumors

March 28, 2014

Xeloda + Oxaliplatin Compares To FOLFOX-4 In First Line

January 30, 2009

New Creatinine Test Raises Questions About Accuracy Of Carboplatin Dosing

October 8, 2010

CTEP Analyses Proposals For Changes In Cooperative Groups

April 25, 1986

Weicker Negotiating For 6,000 NIH Grants In Both 1985, 1986; Societies Appeal For Adequate Funding

May 10, 1985